Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo Efficacy as early as 2 weeks No MACE, uveitis, IBD, deaths @RheumNow #EULAR2022 ABST#LB0001 https://t.co/sHRRwLlChi

72% of you would treat some high-risk subclinical arthralgias with MTX and Marta Mosca, in the #EULAR2022 highlights, broadly agrees OP0070 Leiden data showed better function and presenteeism. And that’s a win in my book @RheumNow https://t.co/BqTLy4HBWR https://t.co/cwzJkH0f71

Biosimilars and COVID vaccines have made nocebo more pertinent than ever. How do we combat it? First line is good communication, and the foot soldiers are the right phrases. Language matters. #EULAR2022 @RheumNow https://t.co/U0Chv9ia1G

#OP0004 #EULAR2022 In line with EULAR President’s preech to go Digital, Prof Mosca highlighted a study which showed assessment of joints in RA could be done by taking photos and analysed their dorsal skin folds using convolutional neural network @RheumNow https://t.co/h03mieTcQt

Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change. In the 2022 version: JAKi now separate sentence following bDMARDs, with proviso to mention risk. Sometimes guidelines have to tell us what we’ve all inevitably been expecting #EULAR2022 @RheumNow https://t.co/RPbPNi3vcW

In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA. @RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7

Rituximab/belimumab patients & COVID vaccination response: may have had average antibody response but there’s still the cellular response to consider too! Not as bad. Still caution++, but when ritux really needed we’ll find a way despite COVID from roundup #EULAR2022 @RheumNow https://t.co/zFr6QI9TOG

#OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial @RheumNow https://t.co/dirmHY9cYJ

Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings. Existing MRI scoring may underserve axSpA in women. Added to therapy differences, a lot to readdress for our female axSpA patients. from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM